Prostata raky erkeklerde dünýä boýunça ikinji iň giň ýaýran rak bolup, 2018 - nji ýylda 1 million 276 müň täze kesel habar berlip, erkeklerde rak keselleriniň 7,1% - i bolupdyr.
Prostata raky üçin ölüm derejesi hem ýokary, 2018 - nji ýylda bütin dünýäde tahminen 37,005 ölüm.
Emma ölüm derejesi etraplara görä örän tapawutlanýar, günbatar Afrikada prostata rak ölüminiň bäşinji iň ýokary howpy bar, we Nigeriýada bu etrabyň iň uly ilaty we ihtisady bar.
Nigeriýada, erkeklerde en köp görülen we ölüm getirýän rak raky bolup, her 100 000 erkekde 32,8 kesel we 16,3 ölüm bar.
Bu Demirgazyk Amerikada ölüm derejesinden iki esse köp.
Keselligiň giç anyklanmagy, anyklamak we anyklamak üçin çäkli serişdeler, we keselleriň belgileýşi we habar bermegiň pesleşmegi Nigeriýada ölüm derejesiniň ýokary bolmagyna goşant goşýar.
ABŞ-da, prostat rak erkeklerde rak ölüminiň ikinji iň köp görlen sebäpidir, her ýyl bu keselden takmynan 40 000 erkek ölýär.
Prostat raky ölüm derejesi 1990-njy ýyllaryň başyndan bäri kem-kemden peselýär, ýöne bu ähmiýetli saglyk aladasy bolup galýar.
Umuman, prostat raky ölümli kesel bolup, esasanam, medisina we skrining serişdelerine ýetimi çäkli ýerlerde.
Emma, irki anyklama we bejergi netijeleri has gowy edip, ölüm derejesini peseldip biler.
Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.
Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.
Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.
Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.
Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.
['Ýagşylykdan ýüz öwürmek: medisina']
['Bu web - saýt diňe bilim we maglumat bermek üçin niýetlenen.']
['Berilen maglumat saglyk meselesini ýa-da keselini anyklamak ýa-da bejermek üçin ulanmaly däl we şahsy lukman maslahatyny gözleýänler lukman bilen maslahatlaşmaly.']
['Soragyň jogabyny döredýän sinir tory sanly maglumat babatda nädogry bolup biler.']
['Her wagt lukmanyňyzyň ýa-da başga bir saglyk hyzmatçysynyň maslahatyny sorap görüň. Bu web-saýtda okan zadyňyz üçin hiç haçan lukmanlaryň maslahatyny äsgermezlik etmäň ýa-da ony soramaga soňa goýmaň. Eger sizde medisina ýagdaýy kyn bolsa, 911-e jaň ediň ýa-da derrew iň golaýdaky hassahana baryň. Bu web-saýt ýa-da onuň ulanylyşy bilen lukman-hassa gatnaşygy döremeýär. BioMedLib-de, onuň işgärleri-de, ýa-da bu web-saýtda goşant goşýanlar-da, bu ýerde berilýän maglumat ýa-da onuň ulanylyşy babatda hiç hili açyk ýa-da örtülü wekilçilik etmeýärler.']
['Ýokary haklar']
['1998-nji ýylyň Digital Millennium Copyright Act, 17 U.S.C. § 512 (DMCA) haky bolanlar üçin Internetde görünýän materiallary ABŞ haky boýunça hukuklaryny bozýar diýip pikir edýänlere çäre görmäge mümkinçilik berýär. ']
['Eger siz biziň web saýtymyz ýa-da hyzmatlarymyz bilen baglanyşykly edip berilýän maglumat ýa-da materiallaryň siziň avtorlyk hukugyňyzy bozýandygyny dogry ynansaňyz, siz (ýa-da wekiliňiz) maglumat ýa-da materiallary aýyrmak ýa-da olara girmegiň bökülmegi barada bize habarlama ýollap bilersiňiz.']
['Habarlamalar elektron poçta arkaly ýazylgy ýollanmaly (elektron poçta jaýyny görmek üçin "Mugallymlar" bölüminde seret).']
['DMCA nusgasyna görä, hakyňy bozmak barada habar bermegiňde şu maglumatlar gerek: (1) hakyňy bozmakda aýyplanýan hakyňy goraýan işiň suratlandyrmasy; (2) hakyňy bozýan maglumatyň suratlandyrmasy we maglumaty tapmaga ýeterlik maglumat; (3) seniň bilen habarlaşmak üçin maglumat, şol sanda seniň adres, telefon we elektron poçtalaryň; (4) seniň hakyňy bozýan maglumatyň hak eýesi ýa-da onuň wekili tarapyndan ýa-da kanun boýunça rugsat berilmändigine gowy ynamyň bardygy barada şaýatlyk.']
['5) Siziň ýalan sözlemek jezasy astynda gol çekip, habarlamada berilýän maglumatyň dogrydigini we siziň bozulan diýip aýyplanýan avtorlyk hukugyny goramaga ygtyýaryňyzyň bardygyny tassyklaýan şaýatlygyňyz;']
['we (6) hak eýesiniň ýa-da hak eýesi adyndan hereket etmäge ygtyýary bolan adamyň fiziki ýa-da elektron goly. ']
['Eger ýokarda agzalan maglumatlaryň ählisini ýazmasaň, şikayetleriňiň çözülmegi giçleşdiriler.']
['Baglanyş']
['Haýsy soragyňyz / teklibiňiz bar bolsa bize email ýollaň.']
How deadly is prostate cancer?
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.
The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.
However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.
In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.
This is more than double the death rate in North America.
Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.
In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.
The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.
Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.
However, early detection and treatment can significantly improve outcomes and reduce mortality rates.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Hakkynda']
['BioMedLib sorag-jawaplaryň döremegine avtomatlaşdyrylan kompýuterleri ulanýar (maşyn öwrenilýän algoritmler).']
['Biz PubMed/Medline-den 35 million sany biomedikal neşirleri we RefinedWeb-den web sahypalary bilen başlaýarys.']
